Article: Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
AuthorsZhao, G1 2
Du, L3
Xiao, W1
Sun, S1
Lin, Y2
Chen, M2
Kou, Z1
He, Y3
Lustigman, S3
Jiang, S3
Zheng, BJ2
Zhou, Y1
KeywordsASP-1
H5N1
M2e
Vaccine
Issue Date2010
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2010, v. 28 n. 44, p. 7233-7240 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2010.08.049
AbstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/j.vaccine.2010.08.049
ISI Accession Number IDWOS:000283980400015
Funding AgencyGrant Number
National 863 Program of China2006AA02Z406
National 973 Program of China2005CB523001
NSFC30901371
Mega-projects of Science Research2009ZX10004-401
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by National 863 Program of China (2006AA02Z406), National 973 Program of China (2005CB523001), NSFC (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

ReferencesReferences in Scopus
GrantsControl of Pandemic and Inter-pandemic Influenza
Cross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
DC Field
Value
dc.contributor.authorZhao, G
dc.contributor.authorDu, L
dc.contributor.authorXiao, W
dc.contributor.authorSun, S
dc.contributor.authorLin, Y
dc.contributor.authorChen, M
dc.contributor.authorKou, Z
dc.contributor.authorHe, Y
dc.contributor.authorLustigman, S
dc.contributor.authorJiang, S
dc.contributor.authorZheng, BJ
dc.contributor.authorZhou, Y
dc.date.accessioned2011-07-27T01:31:07Z
dc.date.available2011-07-27T01:31:07Z
dc.date.issued2010
dc.description.abstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.
dc.description.grantControl of Pandemic and Inter-pandemic Influenza
dc.description.grantCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
dc.description.grantcode97655
dc.description.grantcode101167
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2010, v. 28 n. 44, p. 7233-7240 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2010.08.049
dc.identifier.citeulike7716681
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2010.08.049
dc.identifier.epage7240
dc.identifier.hkuros188636
dc.identifier.isiWOS:000283980400015
Funding AgencyGrant Number
National 863 Program of China2006AA02Z406
National 973 Program of China2005CB523001
NSFC30901371
Mega-projects of Science Research2009ZX10004-401
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by National 863 Program of China (2006AA02Z406), National 973 Program of China (2005CB523001), NSFC (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue44
dc.identifier.openurl
dc.identifier.pmid20732469
dc.identifier.scopuseid_2-s2.0-77957821697
dc.identifier.spage7233
dc.identifier.urihttp://hdl.handle.net/10722/135278
dc.identifier.volume28
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.subject.meshAdjuvants, Immunologic - administration and dosage - pharmacology
dc.subject.meshAntigens, Helminth - administration and dosage - immunology
dc.subject.meshHelminth Proteins - administration and dosage - immunology
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology
dc.subject.meshInfluenza Vaccines - immunology
dc.subjectASP-1
dc.subjectH5N1
dc.subjectM2e
dc.subjectVaccine
dc.titleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
dc.typeArticle
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. New York Blood Center